- This event has passed.
Exploring Endocrine Resistance in Breast Cancer
December 13 at 12:00 pm - 1:00 pm
Robert Clarke, PhD, DSc
Professor of Oncology and Dean of Research
Endocrine therapy has been around since Beatson and others showed the benefit of ovariectomy in the 1890s. Treatment changed over the intervening century to include drugs like Tamoxifen (since 1971). While aromatase inhibitors are currently the preferred first-line therapy for postmenopausal women, and these drugs increase disease free survival relative to Tamoxifen, improvements in overall survival with endocrine therapies have changed little since the 1970s. Lacking in the field has been a framework for understanding how breast cancer cells respond to the stress of an endocrine therapy and the factors that drive resistance. Individual genes have been implicated but few of these have led to regimens that have significantly improved overall survival. A systems-based perspective will be presented in the context of a new framework for understanding endocrine resistance, which may lead to new ways to design treatments that could lead to increases in both disease-free and overall survival rates.
Sponsored by the Breast Cancer Research Group at the University of Illinois Cancer Center.
Lunch will be served.